Clearpoint Neuro Stock Performance
| CLPT Stock | USD 13.46 0.89 7.08% |
The firm shows a Beta (market volatility) of 1.66, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Clearpoint Neuro will likely underperform. At this point, Clearpoint Neuro has a negative expected return of -0.24%. Please make sure to confirm Clearpoint Neuro's total risk alpha, as well as the relationship between the skewness and day median price , to decide if Clearpoint Neuro performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Clearpoint Neuro has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 7.08 | Five Day Return 5.07 | Year To Date Return (4.06) | Ten Year Return 12.17 | All Time Return (55.13) |
Last Split Factor 1:40 | Dividend Date 2016-07-27 | Last Split Date 2016-07-27 |
1 | Disposition of 3555 shares by Dalessandro Danilo of Clearpoint Neuro at 8.1 subject to Rule 16b-3 | 11/21/2025 |
2 | Will ClearPoint Neuro Inc. stock maintain dividend yield - July 2025 Macro Moves Free Daily Entry Point Trade Alerts - Newser | 12/02/2025 |
3 | Stocks With Rising Relative Strength ClearPoint Neuro - Investors Business Daily | 12/09/2025 |
4 | Acquisition by Richards Timothy T. of 725 shares of Clearpoint Neuro at 15.38 subject to Rule 16b-3 | 12/10/2025 |
5 | Does ClearPoint Neuro Have A Healthy Balance Sheet - | 12/22/2025 |
6 | Acquisition by Fletcher R John of 422 shares of Clearpoint Neuro at 13.68 subject to Rule 16b-3 | 01/02/2026 |
7 | ClearPoint Neuro Restructures IRRAS Subsidiary Under Debt Agreement - TipRanks | 01/05/2026 |
8 | Disposition of 20000 shares by Joseph Burnett of Clearpoint Neuro at 16.12 subject to Rule 16b-3 | 01/09/2026 |
9 | Earnings Risk Will ClearPoint Neuro Inc stock deliver better than expected guidance - 2025 Valuation Update Long-Term Growth Portfolio Plans - moha.gov.vn | 01/13/2026 |
10 | While institutions own 40 percent of ClearPoint Neuro, Inc. , individual investors are its largest shareholders with 52 percent ownership | 01/20/2026 |
11 | Disposition of 2943 shares by Joseph Burnett of Clearpoint Neuro at 15.57 subject to Rule 16b-3 | 01/26/2026 |
12 | Insider Selling ClearPoint Neuro CEO Sells 45,822.51 in Stock | 01/27/2026 |
13 | Understanding the Setup and Scalable Risk - Stock Traders Daily | 02/05/2026 |
| Begin Period Cash Flow | 23.1 M | |
| Total Cashflows From Investing Activities | -275 K |
Clearpoint | Build AI portfolio with Clearpoint Stock |
Clearpoint Neuro Relative Risk vs. Return Landscape
If you would invest 1,653 in Clearpoint Neuro on November 10, 2025 and sell it today you would lose (307.00) from holding Clearpoint Neuro or give up 18.57% of portfolio value over 90 days. Clearpoint Neuro is currently does not generate positive expected returns and assumes 4.291% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Clearpoint, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Clearpoint Neuro Target Price Odds to finish over Current Price
The tendency of Clearpoint Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 13.46 | 90 days | 13.46 | about 77.56 |
Based on a normal probability distribution, the odds of Clearpoint Neuro to move above the current price in 90 days from now is about 77.56 (This Clearpoint Neuro probability density function shows the probability of Clearpoint Stock to fall within a particular range of prices over 90 days) .
Clearpoint Neuro Price Density |
| Price |
Predictive Modules for Clearpoint Neuro
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Clearpoint Neuro. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Clearpoint Neuro Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Clearpoint Neuro is not an exception. The market had few large corrections towards the Clearpoint Neuro's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Clearpoint Neuro, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Clearpoint Neuro within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 1.66 | |
σ | Overall volatility | 1.32 | |
Ir | Information ratio | -0.11 |
Clearpoint Neuro Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Clearpoint Neuro for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Clearpoint Neuro can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Clearpoint Neuro generated a negative expected return over the last 90 days | |
| Clearpoint Neuro has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 31.39 M. Net Loss for the year was (18.91 M) with profit before overhead, payroll, taxes, and interest of 21.05 M. | |
| Clearpoint Neuro currently holds about 45.14 M in cash with (8.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84. | |
| Clearpoint Neuro has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Understanding the Setup and Scalable Risk - Stock Traders Daily |
Clearpoint Neuro Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Clearpoint Stock often depends not only on the future outlook of the current and potential Clearpoint Neuro's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Clearpoint Neuro's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27 M | |
| Cash And Short Term Investments | 20.1 M |
Clearpoint Neuro Fundamentals Growth
Clearpoint Stock prices reflect investors' perceptions of the future prospects and financial health of Clearpoint Neuro, and Clearpoint Neuro fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Clearpoint Stock performance.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (0.67) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 398.53 M | ||||
| Shares Outstanding | 29.75 M | ||||
| Price To Earning | (3.36) X | ||||
| Price To Book | 25.26 X | ||||
| Price To Sales | 11.66 X | ||||
| Revenue | 31.39 M | ||||
| Gross Profit | 21.05 M | ||||
| EBITDA | (17.84 M) | ||||
| Net Income | (18.91 M) | ||||
| Cash And Equivalents | 45.14 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 3.57 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 10.33 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (8.95 M) | ||||
| Earnings Per Share | (0.83) X | ||||
| Market Capitalization | 400.41 M | ||||
| Total Asset | 39.19 M | ||||
| Retained Earnings | (191.37 M) | ||||
| Working Capital | 23.01 M | ||||
| Current Asset | 8.1 M | ||||
| Current Liabilities | 1.85 M | ||||
About Clearpoint Neuro Performance
Assessing Clearpoint Neuro's fundamental ratios provides investors with valuable insights into Clearpoint Neuro's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Clearpoint Neuro is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 234.82 | 397.58 | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.79) | (0.83) | |
| Return On Assets | (0.43) | (0.46) | |
| Return On Equity | (0.86) | (0.81) |
Things to note about Clearpoint Neuro performance evaluation
Checking the ongoing alerts about Clearpoint Neuro for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Clearpoint Neuro help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Clearpoint Neuro generated a negative expected return over the last 90 days | |
| Clearpoint Neuro has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 31.39 M. Net Loss for the year was (18.91 M) with profit before overhead, payroll, taxes, and interest of 21.05 M. | |
| Clearpoint Neuro currently holds about 45.14 M in cash with (8.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84. | |
| Clearpoint Neuro has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Understanding the Setup and Scalable Risk - Stock Traders Daily |
- Analyzing Clearpoint Neuro's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clearpoint Neuro's stock is overvalued or undervalued compared to its peers.
- Examining Clearpoint Neuro's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clearpoint Neuro's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clearpoint Neuro's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clearpoint Neuro's stock. These opinions can provide insight into Clearpoint Neuro's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.